Is Cosentyx Safe for Long-Term Use?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, ankylosing spondylitis, and other inflammatory conditions, has been studied for safety over five years in clinical trials and real-world data. Long-term use appears safe for most patients when monitored, with no new safety signals emerging beyond the first year. Common risks like infections stabilize over time, but serious events like inflammatory bowel disease (IBD) or malignancy require ongoing vigilance.[1][2]
What Do Long-Term Clinical Trials Show?
In the FUTURE 5 extension trial, patients on Cosentyx for up to five years maintained efficacy with a safety profile consistent with shorter-term data. Exposure-adjusted incidence rates for serious infections dropped from 1.6 per 100 patient-years in year one to 0.7 in years 4-5. Candida infections peaked early but declined. No increased risk of tuberculosis reactivation or malignancy was linked to duration.[3] Similar patterns held in the CLEAR trial for psoriasis, tracking patients up to four years.[4]
What Real-World Evidence Says About Extended Use?
Post-marketing studies, including registries like the Psoriasis Longitudinal Assessment and Registry (PSOLAR), show Cosentyx users on therapy for 2-5+ years have infection rates comparable to shorter-term users (around 2-3 per 100 patient-years). A 2023 analysis of over 10,000 patients found no cumulative toxicity; discontinuation due to adverse events was low at 5-7% annually.[5] European registries like BADBIR confirm this for psoriasis patients on multi-year treatment.[6]
Common Long-Term Risks and How They're Managed
- Infections: Upper respiratory and candidiasis are most frequent but rarely serious; rates don't rise with time. Prophylactic monitoring and avoiding live vaccines help.
- IBD: Risk (0.1-0.3%) emerges early; screen patients with IBD history before starting and monitor symptoms.
- Malignancy: No dose- or duration-related increase in trials or registries; baseline cancer screening applies.
Annual bloodwork, skin checks, and TB tests mitigate issues. Novartis recommends no predefined limit on duration if benefits outweigh risks.[1][7]
Who Should Avoid or Stop Long-Term Use?
Patients with active IBD, untreated TB, or recent live vaccines face higher risks—discontinue if IBD flares. Pregnancy requires pausing (Category B, limited data). Elderly patients or those on immunosuppressants need closer monitoring for infections.[1][8] No evidence of organ toxicity like liver/kidney damage from extended use.
How Does Cosentyx Compare Long-Term to Other Biologics?
Versus TNF inhibitors (e.g., Humira), Cosentyx shows lower serious infection rates long-term (0.8 vs. 2.5 per 100 patient-years). Against IL-23 inhibitors like Tremfya, safety is similar, but Cosentyx has more candidiasis data from longer exposure.[9] Switching due to loss of efficacy is common after 3-5 years across classes, not unique to Cosentyx.[10]
Sources
[1]: Cosentyx Prescribing Information (Novartis, 2023)
[2]: FDA Label for Secukinumab
[3]: Bachelez et al., Lancet 2018; FUTURE 5 extension
[4]: Blauvelt et al., J Am Acad Dermatol 2021
[5]: Shapiro et al., J Am Acad Dermatol 2023
[6]: BADBIR Registry Data, Br J Dermatol 2022
[7]: Novartis Safety Update, 2023
[8]: Drugs.com Cosentyx Safety
[9]: McInnes et al., Ann Rheum Dis 2022
[10]: Armstrong et al., JAMA Dermatol 2021